| Replagal (agalsidase alfa) / Samaritan Pharma, Takeda |
NCT01196871 / 2010-022709-16: Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease |
|
|
| Completed | 2a | 20 | Canada, US, Europe, RoW | Migalastat HCl, AT1001, Galafold, migalastat, Agalsidase Beta, Fabrazyme, Agalsidase Alfa, Replagal | Amicus Therapeutics | Fabry Disease | 10/12 | 10/12 | | |
NCT00048906: Alpha-Galactosidase A Replacement Therapy for Fabry Disease |
|
|
| Completed | 2 | 3 | US | DRX005B | National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | | 11/03 | | |
2004-000772-14: A Phase I-II Pharmacokinetic/Pharmacodynamic Study of Replagal to Assess the Effects of Alternative Dose and Regimen in Patients with Fabry Disease (TKT027) |
|
|
| Completed | 2 | 20 | Europe | Replagal, Concentrate for solution for infusion, Replagal | TKT Inc | Fabry Disease | | | | |
NCT00071877: An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease |
|
|
| Completed | 2 | 25 | US | Replagal | National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | | 06/05 | | |
NCT00075244: Alternative Dosing and Regimen of Replagal to Treat Fabry Disease |
|
|
| Completed | 2 | 25 | US | Replagal | National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | | 11/05 | | |
NCT00084084: Replagal Enzyme Replacement Therapy for Children With Fabry Disease |
|
|
| Completed | 2 | 17 | Canada, US | Agalsidase alfa, Replagal | Shire | Fabry Disease | 06/11 | 06/11 | | |
NCT01304277: This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes. |
|
|
| Completed | 2 | 17 | Canada | agalsidase alfa, Replagal | Shire | Fabry Disease | 12/12 | 12/12 | | |
NCT01363492: Safety Study of Replagal® Therapy in Children With Fabry Disease |
|
|
| Completed | 2 | 15 | US | Replagal (agalsidase alfa), agalsidase alfa | Shire | Fabry Disease | 04/13 | 04/13 | | |
NCT00068107: Dosing Study of Replagal in Patients With Fabry Disease |
|
|
| Completed | 2 | 13 | US | Replagal, agalsidase alfa | Baylor Research Institute, National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | 12/13 | 12/13 | | |
